Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy.
Eighty-five patients with epithelial ovarian cancer were studied to assess the prognostic value of the prechemotherapy serum concentration of CA125 and its half-life during induction therapy. The endpoints of the analysis were progression rate and time to progression. The prechemotherapy CA125 level had no prognostic value (P = 0.36) if the patients were stratified for tumor size. The half-life of CA125, however, was an independent prognostic variable (P = 0.01). Patients with a half-life of 20 days and more had a 3.2 times higher progression rate and a significantly shorter median time to progression of only 11 months, as compared to 43 months for patients with a half-life of less than 20 days.
van der Burg
M E
ME
Rotterdam Cancer Institute, The Netherlands.
Lammes
F B
FB
van Putten
W L
WL
Stoter
G
G
D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis; D015295:Antigens, Tumor-Associated, Carbohydrate; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology / Q000401:mortality*; D003131:Combined Modality Therapy; D005260:Female; D006207:Half-Life; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000401:mortality*; D011379:Prognosis; D013997:Time Factors
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate